NYXH nyxoah.com: Company Value to Revenue

Official company branding of Nyxoah (NYXH)

The EV/Sales ratio reflects the expansion dynamics of Nyxoah S.A. (NYXH) across US and European markets, where the value of 1660.00 serves as the current metric. Nyxoah S.A. develops autonomous neurostimulators for the control of sleep-disordered breathing. The advantage of compact implants over bulky alternatives enables the brand to maintain pricing power for both its devices and surgical procedures.

nyxoah.com (NYXH): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/21/2026

NYXH (Nyxoah S.A): analytical breakdowns and indicator data

- current quotes and average value forecast:
- company stock capitalization data:
- cash balance and cash flow data:
Initial company analysis:Nyxoah, NYXH
Manufactured products of Nyxoah, S.A.

Nyxoah S.A. is developing apnea treatment systems through partnerships with specialized clinics and research centers. This EV/Sales chart allows for an assessment of how the market capitalizes these technological advancements. The metric compares the total enterprise value, adjusted for net debt, against the volume of generated revenue. This reveals the real value of the business regardless of the debt load. The stability of this indicator confirms the asset's fundamental resilience and protects the investor from overpaying.

Direct competitors

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|Total Company Value-to-Revenue Ratio angiodynamics.com (ANGO)|CERS - Enterprise Value-to-Revenue Ratio|TKNO - EV/Sales Multiple|Monogram Technologies Inc (MGRM) - Enterprise Value-to-Revenue Ratio|STSS - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio InfuSystem Holdings, Inc.|Enterprise Value-to-Revenue Multiple Utah Medical Products UTMD|EV/Sales Multiple KRMD|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple